Page last updated: 2024-11-06

l 693593

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

L 693593: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID65001
CHEMBL ID82439
SCHEMBL ID600199
MeSH IDM0191628

Synonyms (19)

Synonym
2-[2-(5-ethyl-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)ethyl]-2,3-dihydro-1h-isoindole-1,3-dione
chembl82439 ,
bdbm1066
5-ethyl-6-methyl-3-[(2-phthalimido)ethyl]-2-pyridinone
135525-66-5
2-[2-(5-ethyl-6-methyl-2-oxo-1h-pyridin-3-yl)ethyl]isoindoline-1,3-dione
1h-isoindole-1,3(2h)-dione, 2-(2-(5-ethyl-1,2-dihydro-6-methyl-2-oxo-3-pyridinyl)ethyl)-
l-693,593
l 693593
2-[2-(5-ethyl-6-methyl-2-oxo-1h-pyridin-3-yl)ethyl]isoindole-1,3-dione
5-ethyl-6-methyl-3-(2-phthalimidoethyl)pyridin-2(1h)-one
2-(2-(5-ethyl-1,2-dihydro-6-methyl-2-oxo-3-pyridinyl)ethyl)-1h-isoindole-1,3(2h)-dione
SCHEMBL600199
3-(2-phthalimido ethyl)-5-ethyl-6-methylpyridin-2(1h)-one
3-(2-phthalimidoethyl)-5-ethyl-6-methylpyridin-2(1h)-one
OIZHACWNMXZCRJ-UHFFFAOYSA-N
DTXSID00159446
2-(2-(5-ethyl-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)ethyl)isoindoline-1,3-dione
AKOS040752324
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Gag-Pol polyproteinHIV-1 M:B_HXB2RIC50 (µMol)3.70000.00060.91418.3200AID1795290; AID1795378
Reverse transcriptase/RNaseH Human immunodeficiency virus 1IC50 (µMol)3.70000.00011.076810.0000AID198241; AID198397; AID198566
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (2)

Processvia Protein(s)Taxonomy
viral life cycleGag-Pol polyproteinHIV-1 M:B_HXB2R
establishment of integrated proviral latencyGag-Pol polyproteinHIV-1 M:B_HXB2R
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
peptidase activityGag-Pol polyproteinHIV-1 M:B_HXB2R
integrase activityGag-Pol polyproteinHIV-1 M:B_HXB2R
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID198397Tested for inhibition against HIV-1 RT (used (poly)rC-(oligo)dG as the template)1993Journal of medicinal chemistry, Apr-16, Volume: 36, Issue:8
Synthesis and evaluation of 2-pyridinone derivatives as HIV-1-specific reverse transcriptase inhibitors. 4. 3-[2-(Benzoxazol-2-yl)ethyl]-5-ethyl-6-methylpyridin-2(1H)-one and analogues.
AID198566Inhibition of HIV-1 reverse transcriptase.1992Journal of medicinal chemistry, Oct-16, Volume: 35, Issue:21
Synthesis and evaluation of 2-pyridinone derivatives as HIV-1 specific reverse transcriptase inhibitors. 1. Phthalimidoalkyl and -alkylamino analogues.
AID1872682Inhibition of HIV reverse transcriptase2022European journal of medicinal chemistry, Mar-15, Volume: 232A score years' update in the synthesis and biological evaluation of medicinally important 2-pyridones.
AID79232Concentration which inhibited >95% spread of HIV-1 strain IIIb infection in susceptible H-9 cell culture1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
2-Pyridinone derivatives: a new class of nonnucleoside, HIV-1-specific reverse transcriptase inhibitors.
AID199982Inhibition of HIV-1 reverse transcriptase; - = inactive1994Journal of medicinal chemistry, Aug-05, Volume: 37, Issue:16
HIV-1 reverse transcriptase inhibitor design using artificial neural networks.
AID198241Inhibitory activity against HIV-1 reverse transcriptase (RT)1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
2-Pyridinone derivatives: a new class of nonnucleoside, HIV-1-specific reverse transcriptase inhibitors.
AID1795378HIV-1 RT Assay from Article 10.1021/jm00113a036: \\2-Pyridinone derivatives: a new class of nonnucleoside, HIV-1-specific reverse transcriptase inhibitors.\\1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
2-Pyridinone derivatives: a new class of nonnucleoside, HIV-1-specific reverse transcriptase inhibitors.
AID1795290HIV-1 RT Assay from Article 10.1021/jm00099a006: \\Synthesis and evaluation of 2-pyridinone derivatives as HIV-1 specific reverse transcriptase inhibitors. 1. Phthalimidoalkyl and -alkylamino analogues.\\1992Journal of medicinal chemistry, Oct-16, Volume: 35, Issue:21
Synthesis and evaluation of 2-pyridinone derivatives as HIV-1 specific reverse transcriptase inhibitors. 1. Phthalimidoalkyl and -alkylamino analogues.
AID493017Wombat Data for BeliefDocking1992Journal of medicinal chemistry, Oct-16, Volume: 35, Issue:21
Synthesis and evaluation of 2-pyridinone derivatives as HIV-1 specific reverse transcriptase inhibitors. 1. Phthalimidoalkyl and -alkylamino analogues.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's5 (83.33)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.50

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.50 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.50)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (16.67%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (83.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]